While they are documented in patients in remission of testicular cancer, the sequelae of chemotherapy and the impact of the disease and its treatments on the living conditions and QoL of women in remission of rare ovarian cancer remain poorly explored.

The coordinator therefore propose a national 2-step case-control study to evaluate 1) chronic fatigue and QoL and 2) chemotherapy-related sequelae in adult patients in remission of surgery-treated TGMO or TSCS (conservative or not) supplemented with chemotherapy

Inclusion Criteria:

• Age> 18 years;
• Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or sex cords (TSCS) treated optimally;
• Patient who has had surgery and chemotherapy (interest group) or only a surgery (control group);
• Patient in remission more than 2 years after the end of the initial treatment;
• Relapse authorized if remission more than 2 years after the end of the treatment;
• Patient with no other cancers (with the exception of basal cell skin carcinomas, in situ cancers of the breast and cervix);
• Patient having signed his consent to participate

Exclusion Criteria:

• Pregnant or breastfeeding woman;
• Psychiatric pathology that may disrupt the course of the study or prevent the interpretation of results;
• Person deprived of liberty;
• Major subject to a legal protection measure or unable to express his consent.